

1078

1079

1080

1081 SUPPLEMENTAL INFORMATION TITLES AND LEGENDS

1082 **Figure S1. Cachectic phenotype of C26 and KPC murine models.** (A) Graphical summary of the
1083 experimental protocol. (B-C) Weight trajectories of C26 tumor-bearing mice and littermate
1084 controls (C), and KPC tumor-bearing mice and PC controls (C) on KD or NF diets since they were
1085 enrolled into the study until they reached cachectic endpoint. (D-E) Organ weights of cachectic
1086 C26 tumor-bearing mice and littermates (n=10-15) (D), and cachectic KPC tumor-bearing mice
1087 and PC controls (n=9-10) (E) fed either KD or NF diets. (F-G) mRNA expression of the PPAR α
1088 target genes *Acadm* (F) and *Hmgsc2* (G) in C26 tumor-bearing mice and littermate controls fed
1089 KD or NF (n=5-7). (H-I) Cumulative food intake of KD- or NF-fed C26-tumor bearing mice and
1090 littermates (n=5 LM, n=12 C26) (H), and KD- or NF-fed KPC tumor-bearing mice and PC controls
1091 (n=10) (I) during the last 4 days before endpoint.

1092 Data are expressed as the mean \pm SEM. One-way ANOVA with Tukey's correction for post hoc
1093 testing was used in (D-G). Two-way ANOVA statistical tests with Tukey's correction for post hoc
1094 comparisons were performed in (H-I). * p-value < 0.05, ** p-value < 0.01, **** p-value <
1095 0.0001.

1096 **Supplemental Table 1. Macronutrient composition and caloric profile of standard and**
1097 **ketogenic diets.**

1098 **Figure S2. Intratumoral accumulation of lipids and saturation of the GSH system causes**
1099 **ferroptotic cell death.** (A) Schematic representation of the GSH pathway for detoxification of
1100 LPPs. (B) PCA of tumors from C26 tumor-bearing mice fed NF or KD (n=7). (B) PCA of untargeted
1101 metabolomics in the tumors of C26 mice fed KD or NF. (C-F) Quantification of ophthalmate (C),
1102 carnosine (D), hypotaurine (E) and taurine (F) metabolites by UPLC-MS/MS in the tumor of C26
1103 mice fed KD or NF (n=7). (G) Quantification by UPLC-MS/MS of GSH/GSSG ratio in the tumor of
1104 C26 mice fed KD or NF, untreated or treated with NAC (n=5-7). (H) Oil-Red-O staining of tumors
1105 from C26 mice on KD or NF. (I) Western blot of tumor lysates from C26 mice fed KD or NF

1106 stained for Caspase-3 and BAX apoptotic markers (n=5). (J) Immunohistochemistry staining of
1107 tumors from C26 mice fed KD or NF with the proliferation marker Ki67. (K-N) Quantification by
1108 flow cytometry of neutrophils (K), T-cells (L), macrophages (M) and monocytes (N), in the tumor
1109 of C26 mice fed KD or NF (n=3-4).

1110 Data are expressed as the mean \pm SEM. Statistical analysis in (B) is described in the Methods
1111 section/Chapter 4. Statistical differences in (C-F, K-N) were examined using an unpaired two-
1112 tailed Student's t-test with Welch's correction. One-way ANOVA with Tukey's correction for
1113 post hoc testing was used in (G). * p-value < 0.05, ** p-value < 0.01, **** p-value < 0.0001.

1114

1115 **Figure S3. Biochemical deficiency in the corticosterone synthesis pathway in the adrenal**
1116 **cortex of tumor-bearing mice fed ketogenic diet.** (A) Murine synthetic pathway of
1117 corticosterone in the cortex of the adrenal glands. (B) Corticosterone levels at baseline (prior to
1118 diet change), 4 days after the start of the experiment, and at endpoint (cachexia) in C26 tumor-
1119 bearing mice and littermate controls fed KD or NF (n=5 LM, n=10-14 C26). (C) GSEA pathway
1120 analysis of cholesterol homeostasis and steroid biosynthesis in tumor-bearing KD-fed KPC mice
1121 compared to NF-fed KPC (n=5). (D) Plasma concentration of the pro-inflammatory cytokine IL-6
1122 in C26 tumor-bearing mice and control littermates on NF or KD diets at endpoint (n=5 LM, n=9-
1123 10 C26).

1124 Data are expressed as the mean \pm SEM. One-way ANOVA with Tukey's correction for post hoc
1125 testing was used in (B, D). Statistical analysis in (C) is described in Methods. * p-value < 0.05, **
1126 p-value < 0.01, *** p-value < 0.001, **** p-value < 0.0001.

1127 **Figure S4. Extended metabolic profiling of cachectic C26 and KPC mice.** (A-B) Plasma urea
1128 levels in cachectic C26 tumor-bearing mice and littermate controls (n=5 LM, n=10-11 C26) (A),
1129 and cachectic KPC tumor-bearing mice and PC controls (n=5-8) (B) fed either KD or NF diets. (C)
1130 PCA of hepatic metabolomics in C26 tumor-bearing mice and control littermates fed with KD or
1131 NF (n=5-6).

1132 Data are expressed as the mean \pm SEM. One-way ANOVA with Tukey's correction for post hoc
1133 testing was used in (A-B). Statistical analysis in (C) is described in Methods. * p-value < 0.05, **
1134 p-value < 0.01, **** p-value < 0.0001.

1135

1136 **Figure S5. Extended data on the systemic effects of Dexamethasone treatment.** (A) Weight
1137 trajectories of C26 tumor-bearing mice treated with Dexamethasone and fed with either KD or
1138 NF. (B) Survival of littermate controls, and C26 tumor-bearing mice treated or untreated with
1139 Dexamethasone, fed with KD or NF (n=7 LM, n=17-18 C26, n=7 C26 + Dex). (C) Percentage of
1140 mice in each group that were sacrificed because of cachexia (OS) or tumor size (PFS) endpoints.
1141 (D) Quantification by UPLC-MS/MS of metabolites involved in fatty acid metabolism in the liver
1142 of C26 tumor-bearing mice on either KD or NF diets, untreated or treated with Dexamethasone
1143 (n=5). (E) Organ weights of C26 tumor-bearing mice untreated or treated with Dexamethasone
1144 after 4 days of treatment (n=10-12 C26, n=3 C26 + Dex). (F-G) Cumulative water intake (F) and
1145 total movement (G) during the last 4 days before endpoint in littermate controls and C26
1146 tumor-bearing mice, untreated or treated with Dexamethasone, fed KD or NF (n=7).

1147 Data are expressed as the mean \pm SEM. Survival: OS + PFS. Kaplan–Meier curves in (B-C) were
1148 statistically analyzed by using the log-rank (Mantel–Cox) test. One-way ANOVA with Tukey's
1149 correction for post hoc testing was used in (E). Analysis in (D, F-G) is described in Methods. * p-
1150 value < 0.05, ** p-value < 0.01, *** p-value < 0.001, **** p-value < 0.0001.

1151

1152

1153

1154

1155


1156

1157


1158

1159


1160




Supplementary Figure 1




Supplementary Figure 2



Supplementary Figure 3



Supplementary Figure 4



Supplementary Figure 5

	Standard diet (PicoLab Rodent Diet 20)	Ketogenic diet (AIN-76A Modified)
Fat (%)	10.6	75.1
Protein (%)	20	8.6
Carbohydrates (%)	52.9	3.2
Fiber (%)	4.7	4.8
Ash (%)	6.1	3
Moisture (%)	<10	<10
Caloric profile (kcal/g)	4.07	7.24
Cystine (g/kg)	2.8	0.3
Methionine (g/kg)	7	2.2

Extended Data Table 1